- Home
- CNF vs FGEN Comparison
CNF vs FGEN Comparison
Compare CNF & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- FGEN
- Stock Information
- Founded
- CNF 1999
- FGEN 1993
- Country
- CNF China
- FGEN United States
- Employees
- CNF N/A
- FGEN N/A
- Industry
- CNF Finance: Consumer Services
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- FGEN Health Care
- Exchange
- CNF Nasdaq
- FGEN Nasdaq
- Market Cap
- CNF 35.7M
- FGEN 33.5M
- IPO Year
- CNF 2018
- FGEN 2014
- Fundamental
- Price
- CNF $0.78
- FGEN $7.69
- Analyst Decision
- CNF
- FGEN Strong Buy
- Analyst Count
- CNF 0
- FGEN 1
- Target Price
- CNF N/A
- FGEN $250.00
- AVG Volume (30 Days)
- CNF 201.2K
- FGEN 74.7K
- Earning Date
- CNF 08-27-2025
- FGEN 08-05-2025
- Dividend Yield
- CNF N/A
- FGEN N/A
- EPS Growth
- CNF N/A
- FGEN N/A
- EPS
- CNF 0.08
- FGEN N/A
- Revenue
- CNF $85,661,735.00
- FGEN $6,996,000.00
- Revenue This Year
- CNF $252.34
- FGEN N/A
- Revenue Next Year
- CNF N/A
- FGEN N/A
- P/E Ratio
- CNF $10.15
- FGEN N/A
- Revenue Growth
- CNF N/A
- FGEN N/A
- 52 Week Low
- CNF $0.37
- FGEN $4.50
- 52 Week High
- CNF $2.84
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- CNF 61.79
- FGEN 63.73
- Support Level
- CNF $0.60
- FGEN $5.37
- Resistance Level
- CNF $0.83
- FGEN $5.73
- Average True Range (ATR)
- CNF 0.10
- FGEN 0.51
- MACD
- CNF 0.02
- FGEN 0.32
- Stochastic Oscillator
- CNF 80.09
- FGEN 97.26
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.